KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Change in Accured Expenses (2016)

Gsk has reported Change in Accured Expenses over the past 8 years, most recently at -$1.0 billion for Q4 2016.

  • For Q4 2016, Change in Accured Expenses fell 219.84% year-over-year to -$1.0 billion; the TTM value through Dec 2016 reached $607.6 million, up 15.71%, while the annual FY2018 figure was $3.2 billion, 36.48% up from the prior year.
  • Change in Accured Expenses for Q4 2016 was -$1.0 billion at Gsk, down from $246.5 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $855.9 million in Q4 2015 and troughed at -$1.0 billion in Q4 2016.
  • A 5-year average of -$207.4 million and a median of -$430.8 million in 2013 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: soared 198.7% in 2015 and later crashed 219.84% in 2016.
  • Year by year, Change in Accured Expenses stood at -$864.0 million in 2012, then surged by 62.52% to -$323.8 million in 2013, then plummeted by 66.09% to -$537.8 million in 2014, then surged by 259.14% to $855.9 million in 2015, then plummeted by 219.84% to -$1.0 billion in 2016.
  • Business Quant data shows Change in Accured Expenses for GSK at -$1.0 billion in Q4 2016, $246.5 million in Q1 2016, and $855.9 million in Q4 2015.